S.B. Kaye - Concepedia

Author

S.B. Kaye

University of Glasgow

Also Known As

Demetri, G. D., H. Illiger, K Carty, S B Kaye, S D Fossa, S KAYE, S Kaye, S. B. KAYE, S. B. Kaye, S. KAYE

187

Publications

10.3K

Citations

H-Index

Concepts

All Affiliations

University of Glasgow Western Infirmary Beatson West of Scotland Cancer Centre Institute of Cancer Research Royal Marsden Hospital

About

S.B. Kaye is an author at University of Glasgow specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	70	4.3K
2	Health Sciences	7	7	257
3	Public Health	3	3	43
4	Cell Biology	3	3	108
5	Nursing	1	1	158

S.B. Kaye

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
On the receiving end—patient perception of the side-effects of cancer chemotherapy Alan S. Coates, Suzanne Abraham, S.B. Kaye, European Journal of Cancer and Clinical Oncology Palliative CareMedicineCancer ManagementMetronomic TherapyPharmacotherapy	1983	1K
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer John Nemunaitis, Fadlo R. Khuri, Ian Ganly, Journal of Clinical Oncology	2001	472
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. G. Read, Sally Stenning, M.H. Cullen, Journal of Clinical Oncology	1992	424
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. René Bruno, Darcy A. Hille, A. Riva, Journal of Clinical Oncology	1998	418
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. M.H. Cullen, Sally Stenning, M C Parkinson, Journal of Clinical Oncology	1996	318
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. Melanie Mackean, André Planting, Chris Twelves, Journal of Clinical Oncology	1998	266
Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck G. Catimel, Jaap Verweij, Vera Mattijssen, Annals of Oncology Active DrugMedicinePharmacotherapyHead And Neck CancerDermatology	1994	258
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C David Propper, A. McDonald, A. Man, Journal of Clinical Oncology	2001	233
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Anna Jones, A Hill, David Cunningham, The Lancet Emetogenic ChemotherapyOncologyMetronomic TherapyPharmacologyPharmacotherapy	1991	217
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial Andrés Poveda, Ignace Vergote, Sergei Tjulandin, Annals of Oncology	2010	168

Page 1